This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

BonAlive Biomaterials Ltd Receives CE-mark For Osteostimulative BonAliveA® Putty

TURKU, Finland, November 22, 2013 /PRNewswire/ --

BonAlive Biomaterials Ltd ,  a manufacturer of implantable medical devices ,  today announced the launch of a patented ,  ready-to-use and mouldable version of their osteostimulative BonAlive ®   bioactive glass bone regeneration technology.

The launch of the osteostimulative BonAlive ® putty is an important milestone in the commercialization strategy of the BonAlive ® product family. The current BonAlive ® granules products have been approved for orthopaedic use since 2006 and for bone cavity filling in the treatment of chronic osteomyelitis since March 2011. "As an extension to the BonAlive ® granules product line, the BonAlive ® putty will significantly strengthen our position in the trauma and spine market as surgeons are increasingly demanding products that are both easy and ready-to-use while delivering a solid clinical outcome" said Dr. Fredrik Ollila, CEO of BonAlive Biomaterials Ltd.

For more information about BonAlive Biomaterials Ltd, please visit http://www.bonalive.com.

About BonAlive Biomaterials Ltd

BonAlive Biomaterials Ltd is an emerging leader in the field of implantable medical devices for bone regeneration. The company provides world-leading biomaterial solutions for the treatment of chronically infected bone. BonAlive ® products are available in Europe, Middle East, Asia-Pacific, Africa, Brazil and the USA through a professional distributor network. The clinical use of BonAlive ® bioactive glass is supported by a twenty year research history including several randomized prospective trials in the field of spine, benign bone tumour and trauma surgery. More than fifty peer reviewed articles have been published relating to BonAlive ® products.

For questions or additional information ,  please contact: BonAlive Biomaterials Ltd Dr. Fredrik Ollila ,  Chief executive officer Phone:   +358400931209 Email:    fredrik.ollila@bonalive.com

SOURCE BonAlive Biomaterials Ltd

Copyright 2011 PR Newswire. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

DOW 17,730.11 -27.80 -0.16%
S&P 500 2,076.78 -0.64 -0.03%
NASDAQ 5,009.2140 -3.9090 -0.08%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs